

Documento de consenso sobre el manejo de la dislipemia Española de Arteriosclerosis

Clínica E Investigaci3n En Arteriosclerosis

29, 86-91

DOI: 10.1016/j.arteri.2016.11.001

Citation Report

#	ARTICLE	IF	CITATIONS
1	Colesterol no-HDL como marcador de riesgo y objetivo terapéutico. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2018, 30, 72-73.	0.4	0
2	Population and methodology of the SIMETAP study: Prevalence of cardiovascular risk factors, cardiovascular diseases, and related metabolic diseases. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2018, 30, 197-208.	0.1	2
3	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 683-697.	1.1	19
4	Poblaci3n y metodologÃa del estudio SIMETAP: Prevalencia de factores de riesgo cardiovascular, enfermedades cardiovasculares y enfermedades metab3licas relacionadas. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2018, 30, 197-208.	0.4	13
5	No-HDL-cholesterol as risk marker and therapeutic goal. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2018, 30, 72-73.	0.1	0
6	Lipid control and associated risk factors, before suffering from the first cardiovascular event. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 141-151.	0.1	1
7	A comprehensive approach to type 2 diabetes mellitus â€“ A recommendation document. <i>EndocrinologÃa Diabetes Y Nutrici3n (English Ed)</i> , 2019, 66, 443-458.	0.1	3
8	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 75-88.	0.1	6
9	Management of atherogenic dyslipidemia according to current treatment guidelines: DESPEGA study in real clinical practice. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 192-199.	0.3	0
10	Documento de abordaje integral de la diabetes tipo 2. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2019, 66, 443-458.	0.1	24
11	Management of atherogenic dyslipidemia in the primary care setting in Spain. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 203-209.	0.1	0
12	Riesgo cardiovascular residual de origen lipÃdico. Componentes y aspectos fisiopatol3gicos. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 75-88.	0.4	6
13	Prevalencia de hipertrigliceridemia en adultos y factores cardiometab3licos asociados. Estudio SIMETAP-HTG. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 242-255.	0.4	11
14	Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 242-255.	0.1	4
15	Waist Circumference as a Preventive Tool of Atherogenic Dyslipidemia and Obesity-Associated Cardiovascular Risk in Young Adults Males: A Cross-Sectional Pilot Study. <i>Diagnostics</i> , 2020, 10, 1033.	1.3	9
16	Factores cardiometab3licos asociados y prevalencia de concentraciones bajas de colesterol HDL y de dislipidemia aterog3nica. Estudio SIMETAP-DA. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 19-29.	0.4	1
17	Association between adherence to the Mediterranean diet and the prevalence of cardiovascular risk factors. <i>Revista Latino-Americana De Enfermagem</i> , 2020, 28, e3295.	0.4	7
19	Control lipÃdico y factores de riesgo asociados, antes del padecimiento del primer evento cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 141-151.	0.4	1

#	ARTICLE	IF	CITATIONS
20	Management of atherogenic dyslipidemia in the primary care setting in Spain. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 203-209.	0.4	0
21	Control del perfil lipídico global. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 34-41.	0.4	1
22	Evaluation of a nonrandomized workplace health promotion program in a Spanish multinational company and its effects on cardiovascular risk factors and weight-related outcomes. <i>Archives of Community Medicine and Public Health</i> , 2022, 8, 120-127.	0.1	0